Statins and niacin: The end of residual risk therapy?

Combination Therapy In Dyslipidemia

Volumn , Issue , 2015, Pages 37-43

  Mikhailidis, Dimitri P ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84955388325     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/9783319204338_4     Document Type: Chapter

References (43)

1. Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem Biophys. 1955;54:558-559.
2. Guyton JR. Extended-release niacin for modifying the lipoprotein profile. Expert Opin Pharmacother. 2004;5:1385-1398.
3. White Robinson A, Sloan HL, Arnold G. The antilipidemic effects of plain and extended- release niacin. Prev Cardiol. 2000;3:131-135.
4. Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA. 2000;284: 1263-1270.
5. Goldberg A, Alagona Jr. P, Capuzzi DM, et al. Multiple-dose efficacy and safety of an extended- release form of niacin in the management of hyperlipidemia. Am J Cardiol. 2000;85: 1100-1105.
6. Vogt A, Kassner U, Hostalek U, et al. Correction of low HDL cholesterol to reduce cardiovascular risk: practical considerations relating to the therapeutic use of prolonged-release nicotinic acid (Niaspan). Int J Clin Pract. 2007;61:1914-1921.
7. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-1255.
8. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223:405-418.
9. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-1592.
10. Florentin M, Liberopoulos EN, Kei A, et al. Pleiotropic effects of nicotinic acid: beyond high density lipoprotein cholesterol elevation. Curr Vasc Pharmacol. 2011;9:385-400.
11. Parhofer KG. Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia. Vasc Health Risk Manag. 2009; 5:901-908.
12. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255-2267.
13. Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203-212.
14. Agouridis AP, Filippatos TD, Tsimihodimos V, et al. Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism. Expert Rev Cardiovasc Ther. 2011;9: 355-366.
15. Agouridis AP, Filippatos TD, Derdemezis CS, et al. Combination of fenofibrate with nonstatin drug regimens. Curr Pharm Des. 2010;16:3401-3416.
16. Cashin-Hemphill L, Mack WJ, Pogoda JM, et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA. 1990;264:3013-3017.
17. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
18. Whitney EJ, Krasuski RA, Personius BE, et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med. 2005;142:95-104.
19. Birjmohun RS, Hutten BA, Kastelein JJ, et al. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005;45:185-197.
20. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med. 1989;226:271-276.
21. Bays HE, Maccubbin D, Meehan AG, et al. Blood pressure-lowering effects of extended- release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients. Clin Ther. 2009;31:115-122.
22. Kei A, Elisaf M, Moutzouri E, et al. Add-on-Statin Extended Release Nicotinic Acid/Laropiprant but Not the Switch to High-Dose Rosuvastatin Lowers Blood Pressure: an Open- Label Randomized Study. Int J Hypertens. 2011;2011:830-434.
23. Kuvin JT, Dave DM, Sliney KA, et al. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol. 2006;98:743-745.
24. Kei A, Tellis C, Liberopoulos E, et al. Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia. Cardiovasc Ther. 2014;32:139-146.
25. Florentin M, Liberopoulos EN, Wierzbicki AS, et al. Multiple actions of high-density lipoprotein. Curr Opin Cardiol. 2008;23:370-378.
26. Guyton JR, Brown BG, Fazio S, et al. Lipid-altering efficacy and safety of ezetimibe/simvas- tatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlip- idemia. J Am Coll Cardiol. 2008;51:1564-1572.
27. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med. 2002;162:1568-1576.
28. Thoenes M, Oguchi A, Nagamia S, et al. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome. Int J Clin Pract. 2007;61:1942-1948.
29. Owada A, Suda S, Hata T. Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: a randomized trial. Am J Med. 2003; 114: 347-353.
30. Cho KH, Kim HJ, Kamanna VS, et al. Niacin improves renal lipid metabolism and slows progression in chronic kidney disease. Biochim Biophys Acta. 2010; 1800: 6-15.
31. Salama RH, Nassar AY, Nafady AA, et al. A novel therapeutic drug (copper nicotinic acid complex) for non-alcoholic fatty liver. Liver Int. 2007;27:454-464.
32. Athyros VG, Katsiki N, Karagiannis A, et al. Statins and nonalcoholic fatty liver disease: a bright future? Expert Opin Investig Drugs. 2013;22:1089-1093.
33. Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis. 2010;210: 353-361.
34. Stein EA, Davidson MH, Dujovne CA, et al. Efficacy and Tolerability of Low-dose Simvastatin and Niacin, Alone and in Combination, in patients with combined hyperlipidemia: a prospective trial. J Cardiovasc Pharmacol Ther. 1996;1:107-116.
35. Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol. 2002;89:672-678.
36. McKenney JM, Jones PH, Bays HE, et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis. 2007;192:432-437.
37. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512-3517.
38. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin. 2006;22:2243-2250.
39. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009;361:2113-2122.
40. Paraskevas KI, Veith FJ, Mikhailidis DP. Carotid intima-media thickness and ezetimibe: the end of a misunderstanding? Curr Vasc Pharmacol. 2011;9:381-384.
41. Kalil RS, Wang JH, de Boer IH, et al. Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM-HIGH trial. Kidney Int 2015;87:1250-1257.
42. Agouridis AP, Mikhailidis DP. Should we consider ezetimibe to reach even lower LDL-C targets? Curr Med Res Opin. 2015;31:459-460.
43. Filippatos TD, Elisaf MS. Are lower levels of LDL-cholesterol really better? looking at the results of IMPROVE-IT: opinions of three experts - III. Hellenic J Cardiol. 2015;56:7-9.